GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TE: 0260-2430027 / 2400639
E-mail:hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/74 November 2, 2026

To,

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East, Mumbai 400051
Symbol: GUJTHEM

Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai 400001

Scrip Code: 506879

Dear Sir / Madam,

Sub: Schedule of Investor & Analyst Meet for the Company's Q2 & H1 FY27 Results

With reference to our earlier intimation dated October 27, 2026, we would like to further inform you that an Investor & Analyst Meet is rescheduled as mentioned below (instead of November 5, 2026 as announced earlier).

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Schedule of Investor & Analyst Meet.

No.	Date	Details	Time	Mode	Nature of meeting
1	November 16, 2026	Investor & Analyst Meet of Gujarat Themis Biosyn Limited to discuss the Q2 & H1 FY27 Financial Results.	4:00 p.m. onwards	Phyiscal	Investor Group

Details of the above meet is attached herewith

This is for your information and record.

Thanking you

Yours faithfully

For Gujarat Themis Biosyn Limited

VINEET GANESH GAWANKAR
Digitally signed by VINEET GANESH GAWANKAR
Date: 2026.11.02 15:57:54 +05'30'

Vineet Gawankar
Company Secretary & Compliance Officer

Encl.: as above

Gujarat Themis
Biosyn Limited

The Management of

Gujarat Themis Biosyn Limited

Cordially invites you to the

Investor & Analyst Meet

For the Company's Q2 & H1 FY27 Results

Date/Time
Monday, 16th November 2026
4:00 PM onwards

Venue
Sofitel, Bandra Kurla Complex, Mumbai.

We look forward to your participation

RSVP

Ms. Kashmira Parkar
98206 12098
kashmira.parkar@adfactorspr.com

Ms. Sharmin Vatcha
99207 14214
sharmin.vatcha@adfactorspr.com

ADFACTORS PR
Reputation & Critical Issues Advisory